Welcome to our dedicated page for Grail SEC filings (Ticker: GRAL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biotech disclosures can feel like a second language—especially when GRAIL’s 10-K spells out hundreds of pages of clinical trial statistics, cash-burn tables, and regulatory risk factors tied to its Galleri multi-cancer early detection test. Finding the pivotal trial read-outs or decoding executive stock moves before major data releases shouldn’t require a medical degree.
Stock Titan’s platform turns that challenge into a two-minute task. Our AI-powered summaries convert dense narratives into plain English, so understanding GRAIL SEC documents with AI is as direct as reading a headline. Receive real-time alerts the moment a GRAIL Form 4 insider transactions real-time notice hits EDGAR, review a distilled GRAIL quarterly earnings report 10-Q filing, or open a GRAIL 8-K material events explained brief that pinpoints new clinical milestones.
Use the filings that matter most:
- GRAIL annual report 10-K simplified – track R&D outlays, patent positions, and Galleri commercialization strategy.
- 10-Q trends – rapid GRAIL earnings report filing analysis for cash-runway checks.
- GRAIL insider trading Form 4 transactions – uncover buying or selling before clinical data drops.
- GRAIL proxy statement executive compensation – see how trial success metrics drive pay packages.
Whether you’re monitoring GRAIL executive stock transactions Form 4 or verifying a new partnership disclosed in an 8-K, our comprehensive, continuously updated library ensures GRAIL SEC filings explained simply. Skip the jargon, focus on the insight, and make faster, better-informed decisions about this precision-oncology pioneer.
GRAIL, Inc. (GRAL) reported an insider tax-related stock sale by its Chief Financial Officer. On 11/17/2025, the CFO disposed of 1,697 shares of common stock in an automatic sell-to-cover transaction at a weighted average price of $79.2 per share. These sales were executed by a broker to cover withholding taxes due upon the vesting and delivery of an equity award, rather than as a discretionary open-market sale.
After this transaction and a small correction of 10 shares to fix a prior reporting error, the reporting person beneficially owns 284,077 shares of GRAIL common stock, including 641 shares acquired through the company’s employee stock purchase plan on November 14, 2025.
GRAIL, Inc. reported an insider transaction on a Form 4 involving a large sale of common stock. On 11/17/2025, a reporting person sold 1,000,000 shares of common stock, par value $0.001 per share, in an open-market transaction coded "S" at a price of $79.85 per share. After this sale, the reporting person beneficially owned 3,502,126 shares of GRAIL common stock in direct ownership form.
The remarks state that following this sale, the reporting person is no longer a 10% beneficial owner of GRAIL, and the filing is characterized as an exit filing by the reporting person. The form is filed for a single reporting person and indicates the transaction was not reported as part of a derivative security.
GRAIL, Inc. reported two capital markets updates. The company filed a prospectus supplement for the resale of 3,925,767 shares of common stock previously issued to selling stockholders, consisting of 1,927,194 shares and 1,998,573 shares issuable upon exercise of pre-funded warrants. These securities were issued under a securities purchase agreement dated October 18, 2025 and are covered by GRAIL’s Form S-3 shelf.
GRAIL also entered an Equity Distribution Agreement with Morgan Stanley and TD Securities to establish an at-the-market program allowing sales of up to $300,000,000 of common stock from time to time. Sales may be made in transactions permitted by Rule 415, with a commission of up to 3.0% of gross proceeds payable to the sales agents. Related legal opinions and the agreement were filed as exhibits.
GRAIL, Inc. launched an at‑the‑market offering of up to $300,000,000 in common stock under a prospectus supplement to its shelf registration. Sales may be made from time to time through Morgan Stanley & Co. LLC and TD Securities (USA) LLC as sales agents or principals in transactions deemed an “at the market offering” on Nasdaq or otherwise at market-related or negotiated prices.
The sales agents will earn up to 3.0% of the gross sales price per share. Proceeds will go to GRAIL, and the company currently intends to use the net proceeds to fund commercial activities and reimbursement efforts, as well as for working capital and other general corporate purposes.
GRAIL’s common stock trades on Nasdaq as “GRAL”; the last reported sale price was $83.20 per share on November 13, 2025. Shares outstanding were 36,160,998 as of September 30, 2025. Under the equity distribution agreement, the total number of shares sold pursuant to the program will not exceed 6,900,000.
GRAIL, Inc. filed a prospectus supplement for the resale of up to 3,925,767 shares of common stock by selling stockholders. The registration covers 1,927,194 outstanding common shares and 1,998,573 shares issuable upon exercise of pre-funded warrants.
The company is not selling shares and will not receive proceeds from holder sales; it would receive the nominal $0.001 per-share exercise price if pre-funded warrants are exercised for cash. Selling holders may use various methods of sale, including brokerage transactions, block trades, privately negotiated deals and short sales after the registration statement is declared effective.
Examples include Deep Track Biotechnology Master Fund, Ltd. 927,909 and Farallon affiliates 571,021. Shares outstanding were 38,981,593 as of October 31, 2025. GRAL trades on Nasdaq Global Select Market; the last reported sale price was $84.77 on November 12, 2025.
GRAIL, Inc. (GRAL) reported Q3 2025 results. Total revenue was $36,194 (thousands), up from $28,652 (thousands) a year ago, driven mainly by screening revenue of $32,807 (thousands). Net loss narrowed to $88,977 (thousands), or $2.46 per share, from $125,688 (thousands) a year earlier as operating expenses declined.
Cash and cash equivalents were $126,892 (thousands) and short‑term marketable securities were $413,238 (thousands) as of September 30, 2025. Year‑to‑date, operating cash use was $235,222 (thousands). Management states existing cash, cash equivalents, and short‑term marketable securities will be sufficient for at least the next 12 months. Total assets were $2,601,031 (thousands) with stockholders’ equity of $2,239,963 (thousands). As of November 10, 2025, common shares outstanding were 38,982,223.
GRAIL, Inc. entered into a Securities Purchase Agreement for a private placement of 4,639,543 shares of common stock (or pre-funded warrants with a $0.001 exercise price) at $70.05 per share, for approximate gross proceeds of $325.0 million. Closing is expected on October 21, 2025.
The pre-funded warrants are immediately exercisable and include a Beneficial Ownership Limitation of 4.99% or 9.99% (holder election), which may be increased upon 61 days’ notice up to 19.99%. GRAIL agreed to file a resale registration statement within 30 days after closing and use reasonable best efforts to obtain effectiveness within 60 days of filing or within 5 business days after an SEC no-review notice. The transaction is exempt under Section 4(a)(2) and Regulation D.
GRAIL, Inc. (GRAL) disclosed a routine director equity grant. On October 15, 2025, director William Chase received 275 deferred stock units in lieu of
GRAIL, Inc. agreed to a private placement with Samsung C&T and Samsung Electronics Singapore for 1,570,308 common shares at $70.05 per share, pursuant to a Stock Purchase Agreement. Closing is conditioned on regulatory clearances, including CFIUS, and execution by January 31, 2026 of a business collaboration with Samsung C&T for exclusive Galleri commercialization in Korea and a strategic collaboration with Samsung Electronics.
The company plans to use net proceeds for general corporate purposes to support commercialization and reimbursement efforts. GRAIL will file a resale registration covering the shares within 180 days after closing.
GRAIL also disclosed preliminary Q3 2025 results: US screening revenue between $32.1–$33.1 million, total revenue between $35.7–$36.7 million, and losses from operations between $123.9–$126.9 million. Cash, cash equivalents, restricted cash and short-term marketable securities were approximately $547 million as of September 30, 2025. These figures are preliminary and unaudited.
GRAIL, Inc. (GRAL) reported a director equity grant on Form 4. On October 15, 2025, director Gregory Summe received 425 deferred stock units under the company’s deferred stock program and 2024 Equity Incentive Plan in lieu of $32,136.99 of cash director fees, based on the $75.52 closing price of the company’s common stock on the grant date. The awards vest immediately.
Following this transaction, Mr. Summe beneficially owned 38,794 shares, held directly.
FAQ
What is the current stock price of Grail (GRAL)?
What is the market cap of Grail (GRAL)?
